Reducing cardiometabolic risk with semaglutide in type 1 diabetes (RESET1): Study protocol of a phase 2 double-blinded randomised placebo-controlled trial

What Was Tested

This clinical study looks at Semaglutide.

Therapies are urgently needed to address cardiovascular risk in this group.

Who Took Part

The study group was 60 adults.

PubMed indexes the participants as adults, middle-aged adults and older adults, both men and women.

How the Study Was Run

In design terms this was a randomized, double-blind and placebo-controlled study.

The adults were allocated by chance, so the Semaglutide group and the comparison group should start out alike.

Blinding on both sides kept the adults and researchers unaware of who received Semaglutide.

Some adults received a placebo instead of Semaglutide, giving a reference point.

The primary outcome is carotid femoral pulse wave velocity, a measure of arterial stiffness, as a surrogate marker of cardiovascular risk.

Potential mechanisms for metabolic changes will be explored including change in insulin sensitivity determined by hyperinsulinaemic-euglycaemic clamp; and incretin and pancreatic hormone action measured during mixed meal tolerance test.

What Was Measured

PubMed files the paper under topics including Cardiometabolic Risk Factors, Cardiovascular Diseases, Diabetes Mellitus, Type 1, Glucagon-Like Peptides, Hypoglycemic Agents, Clinical Trials, Phase II as Topic and Randomized Controlled Trials as Topic.

Author keywords: insulin resistance, metabolism, semaglutide and type 1 diabetes.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Semaglutide in 60 adults.

Results are reported in around 2 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2024 (Diabetic medicine : a journal of the British Diabetic Association), a journal based in England.

More context: the Semaglutide compound page, all human trials.